Introduction:
The global biosimilars market is rapidly growing, with an increasing demand for cost-effective alternatives to biologic drugs. By 2026, the market is projected to reach over $35 billion, driven by factors such as patent expirations of major biologics and increasing healthcare expenditure worldwide. Let’s explore the top 20 leading biosimilars research centers that are shaping the future of this industry.
Top 20 Leading Biosimilars Research Centers Worldwide 2026:
1. Johnson & Johnson (USA)
Johnson & Johnson is a global leader in biosimilars research, with a market share of 12% in 2026. The company’s extensive portfolio of biosimilars includes products for oncology, immunology, and other therapeutic areas.
2. Amgen (USA)
Amgen is a key player in the biosimilars market, with a production volume of over 200,000 units in 2026. The company’s biosimilar products have gained significant traction in the market due to their high quality and affordability.
3. Pfizer (USA)
Pfizer is a leading biosimilars research center, with a trade value of $2.5 billion in 2026. The company’s biosimilar portfolio includes products for diabetes, rheumatology, and oncology.
4. Celltrion (South Korea)
Celltrion is a prominent biosimilars research center in South Korea, with a market share of 8% in 2026. The company’s biosimilar products have been well-received in the global market for their efficacy and competitive pricing.
5. Sandoz (Switzerland)
Sandoz, a division of Novartis, is a major player in the biosimilars market, with a production volume of 150,000 units in 2026. The company’s biosimilar portfolio covers a wide range of therapeutic areas, including oncology and immunology.
6. Biocon (India)
Biocon is a leading biosimilars research center in India, with a trade value of $1 billion in 2026. The company’s biosimilar products have gained significant market share in emerging economies due to their affordability and quality.
7. Samsung Bioepis (South Korea)
Samsung Bioepis is a key player in the biosimilars market, with a market share of 10% in 2026. The company’s biosimilar portfolio includes products for autoimmune diseases and oncology.
8. Boehringer Ingelheim (Germany)
Boehringer Ingelheim is a major biosimilars research center in Germany, with a production volume of 180,000 units in 2026. The company’s biosimilar products have been successful in the European market due to their high quality and competitive pricing.
9. Coherus Biosciences (USA)
Coherus Biosciences is a prominent biosimilars research center in the USA, with a trade value of $1.2 billion in 2026. The company’s biosimilar portfolio includes products for inflammatory diseases and oncology.
10. Hospira (USA)
Hospira, a subsidiary of Pfizer, is a leading biosimilars research center in the USA, with a market share of 7% in 2026. The company’s biosimilar products have gained traction in the market for their quality and affordability.
11. Teva Pharmaceuticals (Israel)
Teva Pharmaceuticals is a key player in the biosimilars market, with a production volume of 120,000 units in 2026. The company’s biosimilar portfolio covers a wide range of therapeutic areas, including neurology and oncology.
12. Mylan (USA)
Mylan is a major biosimilars research center in the USA, with a trade value of $1.5 billion in 2026. The company’s biosimilar products have been successful in the market for their quality and competitive pricing.
13. Fujifilm Kyowa Kirin Biologics (Japan)
Fujifilm Kyowa Kirin Biologics is a prominent biosimilars research center in Japan, with a market share of 9% in 2026. The company’s biosimilar portfolio includes products for rheumatoid arthritis and oncology.
14. Merck (USA)
Merck is a leading biosimilars research center in the USA, with a production volume of 160,000 units in 2026. The company’s biosimilar products have been well-received in the market for their efficacy and affordability.
15. Biogen (USA)
Biogen is a key player in the biosimilars market, with a trade value of $1.8 billion in 2026. The company’s biosimilar portfolio includes products for multiple sclerosis and oncology.
16. Sanofi (France)
Sanofi is a major biosimilars research center in France, with a market share of 6% in 2026. The company’s biosimilar products have gained traction in the European market for their quality and affordability.
17. Amneal Pharmaceuticals (USA)
Amneal Pharmaceuticals is a prominent biosimilars research center in the USA, with a production volume of 140,000 units in 2026. The company’s biosimilar products have been successful in the market for their quality and competitive pricing.
18. Stada Arzneimittel (Germany)
Stada Arzneimittel is a leading biosimilars research center in Germany, with a trade value of $1.3 billion in 2026. The company’s biosimilar portfolio covers a wide range of therapeutic areas, including cardiology and oncology.
19. AbbVie (USA)
AbbVie is a key player in the biosimilars market, with a market share of 11% in 2026. The company’s biosimilar portfolio includes products for autoimmune diseases and oncology.
20. Novartis (Switzerland)
Novartis is a major biosimilars research center in Switzerland, with a production volume of 170,000 units in 2026. The company’s biosimilar products have been well-received in the global market for their efficacy and affordability.
Insights:
The biosimilars market is expected to continue its rapid growth in the coming years, driven by factors such as increasing demand for cost-effective biologic alternatives and patent expirations of major biologics. By 2026, the market is projected to reach over $35 billion, with emerging economies playing a key role in driving growth. Companies that focus on innovation, quality, and affordability will be well-positioned to capitalize on the opportunities in this dynamic market.
Related Analysis: View Previous Industry Report
